Robert D Carlson
Overview
Explore the profile of Robert D Carlson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
66
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baybutt T, Entezari A, Caspi A, Staudt R, Carlson R, Waldman S, et al.
Cancer Biol Ther
. 2024 Sep;
25(1):2398801.
PMID: 39315411
Despite success in treating some hematological malignancies, CAR-T cells have not yet produced similar outcomes in solid tumors due, in part, to the tumor microenvironment, poor persistence, and a paucity...
2.
Cao M, Carlson R, Staudt R, Snook A
Methods Cell Biol
. 2024 Mar;
183:303-315.
PMID: 38548415
This chapter introduces four commonly used in vitro chimeric antigen receptor (CAR)-T cell cytotoxicity assays (lactate dehydrogenase release assay, Cr release assay, IncuCyte live cell killing assay, and xCELLigence real-time...
3.
Flickinger Jr J, Staudt R, Singh J, Carlson R, Barton J, Baybutt T, et al.
NPJ Vaccines
. 2022 Jun;
7(1):61.
PMID: 35739202
Strategies to augment immunity to self/neoantigens expressed by cancers are urgently needed to expand the proportion of patients benefiting from immunotherapy, particularly for GI cancers where only a fraction of...
4.
Flickinger Jr J, Singh J, Yarman Y, Carlson R, Barton J, Waldman S, et al.
Front Immunol
. 2022 Mar;
13:855759.
PMID: 35355987
The Gram-positive bacterium (Lm) is an emerging platform for cancer immunotherapy. To date, over 30 clinical trials have been initiated testing Lm cancer vaccines across a wide variety of cancers,...
5.
Lisby A, Carlson R, Baybutt T, Weindorfer M, Snook A
Methods Cell Biol
. 2022 Feb;
167:81-98.
PMID: 35153000
This chapter describes the most common method for evaluating cytotoxicity of chimeric antigen receptor (CAR) T cells, the xCELLigence real-time cell analysis (RTCA) platform (Agilent Technologies, Inc., Santa Clara, CA)....
6.
Staudt R, Carlson R, Snook A
Cancer Biol Ther
. 2022 Feb;
23(1):127-133.
PMID: 35129050
The immune system is capable of remarkably potent and specific efficacy against infectious diseases. For decades, investigators sought to leverage those characteristics to create immune-based therapies (immunotherapy) that might be...
7.
Kopenhaver J, Carlson R, Snook A
Toxins (Basel)
. 2020 Jun;
12(6).
PMID: 32585926
The level of complexity in a disease like cancer presents a number of challenges for effective treatment development, which require significant innovation to overcome [...].
8.
Carlson R, Flickinger Jr J, Snook A
Toxins (Basel)
. 2020 Apr;
12(4).
PMID: 32283684
The ability of the immune system to precisely target and eliminate aberrant or infected cells has long been studied in the field of infectious diseases. Attempts to define and exploit...